MX2021002761A - Metodos para tratar la pancreatitis. - Google Patents
Metodos para tratar la pancreatitis.Info
- Publication number
- MX2021002761A MX2021002761A MX2021002761A MX2021002761A MX2021002761A MX 2021002761 A MX2021002761 A MX 2021002761A MX 2021002761 A MX2021002761 A MX 2021002761A MX 2021002761 A MX2021002761 A MX 2021002761A MX 2021002761 A MX2021002761 A MX 2021002761A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating pancreatitis
- treating
- subject
- pancreatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729354P | 2018-09-10 | 2018-09-10 | |
| PCT/US2019/050262 WO2020055768A1 (en) | 2018-09-10 | 2019-09-09 | Methods for treating pancreatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002761A true MX2021002761A (es) | 2021-05-31 |
Family
ID=69776851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002761A MX2021002761A (es) | 2018-09-10 | 2019-09-09 | Metodos para tratar la pancreatitis. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12378320B2 (https=) |
| EP (1) | EP3849605A4 (https=) |
| JP (1) | JP7560445B2 (https=) |
| KR (1) | KR20210073515A (https=) |
| CN (2) | CN120267815A (https=) |
| AU (1) | AU2019337564A1 (https=) |
| BR (1) | BR112021004444A2 (https=) |
| CA (1) | CA3112382A1 (https=) |
| CL (2) | CL2021000585A1 (https=) |
| IL (1) | IL281343A (https=) |
| MX (1) | MX2021002761A (https=) |
| SG (1) | SG11202102416SA (https=) |
| WO (1) | WO2020055768A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202102416SA (en) | 2018-09-10 | 2021-04-29 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
| US20250297027A1 (en) * | 2021-01-12 | 2025-09-25 | Yeda Research And Development Co. Ltd. | Antibodies to cancer glycosylation and uses thereof |
| JP2024511189A (ja) * | 2021-03-26 | 2024-03-12 | ビオンテック・ソシエタス・エウロパエア | がんの処置における抗ｃａ１９－９抗体およびｆｏｌｆｉｒｉｎｏｘを用いた組合せ療法。 |
| US20250302409A1 (en) * | 2024-03-26 | 2025-10-02 | Hepatiq, Inc. | Determining pancreas disease using functional imaging |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4471057A (en) | 1981-06-30 | 1984-09-11 | The Wistar Institute | Detection of colorectal carcinoma |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| JPS63159763A (ja) * | 1986-12-24 | 1988-07-02 | Fujirebio Inc | 逆受身凝集反応試薬 |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| US7238715B2 (en) | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| HUE026444T2 (en) | 2005-08-05 | 2016-05-30 | Araim Pharmaceuticals Inc | Tissue protection peptides and their use |
| FI20070853A0 (fi) * | 2007-11-09 | 2007-11-09 | Glykos Finland Oy | Glykaania sitovat monoklonaaliset vasta-aineet |
| WO2009094172A2 (en) | 2008-01-22 | 2009-07-30 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| JP5919604B2 (ja) | 2008-08-08 | 2016-05-18 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 抗膵癌抗体 |
| EP3385277A1 (en) | 2013-03-15 | 2018-10-10 | F. Hoffmann-La Roche AG | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| HK1223298A1 (zh) | 2013-07-17 | 2017-07-28 | 阿拉伊姆药品公司 | 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 |
| KR102313341B1 (ko) * | 2013-08-26 | 2021-10-18 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산 |
| CN104623639A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | 白介素22二聚体在制备治疗胰腺炎药物中的应用 |
| PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| SG11202102416SA (en) | 2018-09-10 | 2021-04-29 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
-
2019
- 2019-09-09 SG SG11202102416SA patent/SG11202102416SA/en unknown
- 2019-09-09 BR BR112021004444-2A patent/BR112021004444A2/pt unknown
- 2019-09-09 CA CA3112382A patent/CA3112382A1/en active Pending
- 2019-09-09 KR KR1020217008242A patent/KR20210073515A/ko not_active Ceased
- 2019-09-09 AU AU2019337564A patent/AU2019337564A1/en active Pending
- 2019-09-09 JP JP2021513309A patent/JP7560445B2/ja active Active
- 2019-09-09 CN CN202510438979.9A patent/CN120267815A/zh active Pending
- 2019-09-09 EP EP19859491.3A patent/EP3849605A4/en active Pending
- 2019-09-09 US US17/274,783 patent/US12378320B2/en active Active
- 2019-09-09 CN CN201980073543.7A patent/CN113056286B/zh active Active
- 2019-09-09 WO PCT/US2019/050262 patent/WO2020055768A1/en not_active Ceased
- 2019-09-09 MX MX2021002761A patent/MX2021002761A/es unknown
-
2021
- 2021-03-09 CL CL2021000585A patent/CL2021000585A1/es unknown
- 2021-03-09 IL IL281343A patent/IL281343A/en unknown
-
2022
- 2022-01-13 CL CL2022000091A patent/CL2022000091A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3849605A4 (en) | 2022-06-15 |
| KR20210073515A (ko) | 2021-06-18 |
| CN113056286A (zh) | 2021-06-29 |
| EP3849605A1 (en) | 2021-07-21 |
| CL2022000091A1 (es) | 2022-11-18 |
| CL2021000585A1 (es) | 2021-08-13 |
| IL281343A (en) | 2021-04-29 |
| US20220049011A1 (en) | 2022-02-17 |
| CA3112382A1 (en) | 2020-03-19 |
| SG11202102416SA (en) | 2021-04-29 |
| BR112021004444A2 (pt) | 2021-06-01 |
| AU2019337564A1 (en) | 2021-05-06 |
| US12378320B2 (en) | 2025-08-05 |
| CN113056286B (zh) | 2025-04-29 |
| CN120267815A (zh) | 2025-07-08 |
| JP2022500382A (ja) | 2022-01-04 |
| JP7560445B2 (ja) | 2024-10-02 |
| WO2020055768A1 (en) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001189A1 (es) | Anticuerpos para cd40. (divisional de solicitud n° 2017003427) | |
| CL2018002708A1 (es) | Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis | |
| CL2025000403A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| MX2022001133A (es) | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). | |
| SV2017005380A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| CL2019000585A1 (es) | Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos. | |
| MX2022004000A (es) | Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon. | |
| MX2018009680A (es) | Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3. | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| MX2016005801A (es) | Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk. | |
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2017014977A (es) | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2. | |
| MA67901B1 (fr) | Mirikizumab pour le traitement de la colite ulcéreuse | |
| MX2021003298A (es) | Métodos para revertir la actividad ticagrelor. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| AR107893A1 (es) | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE | |
| CL2022002410A1 (es) | Terapia combinada de inhibidores axl/mer y pd-1/pd-l1. | |
| MX2022012913A (es) | Anticuerpo anti-ox40 y usos del mismo. | |
| CL2021003335A1 (es) | Anticuerpo biespecífico para a-syn/igf1r y uso de este. | |
| CL2024003486A1 (es) | Anticuerpo anti-b7h3 y usos del mismo | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. |